Alere Inc (ALR)

39.91
NYSE : Health Care
Prev Close 39.67
Day Low/High 39.68 / 40.49
52 Wk Low/High 31.47 / 54.13
Avg Volume 731.80K
Exchange NYSE
Shares Outstanding 87.00M
Market Cap 3.45B
EPS 2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Alere Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Alere Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Alere Inc.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Alere Inc.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Alere Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Alere Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Alere Inc.

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union regulators are expected to approve Abbott Laboratories' $33 billion acquisition of St. Jude Medical.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Alere Inc. And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Alere Inc. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Alere Inc.

Alere (ALR) Stock Tumbles, Removed From Medicare After Billing Dead People

Alere (ALR) Stock Tumbles, Removed From Medicare After Billing Dead People

Alere (ALR) allegedly submitted claims to Medicare for 211 deceased people.

Abbott Files Breach of Contract Suit Against Alere

Abbott Files Breach of Contract Suit Against Alere

Abbott wants more information from Alere, as promised under their pending $7.9 billion agreement.

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.

Abbott, St. Jude Float Antitrust Spinoff by FTC

Abbott, St. Jude Float Antitrust Spinoff by FTC

They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.

St. Jude Device Failures Won't Ruin Abbott Deal

St. Jude Device Failures Won't Ruin Abbott Deal

St. Jude Medical's defibrillators are having problems with batteries, but this likely won't affect Abbott Laboratories' acquisition of the medical device maker.

Mediation Talks Between Abbott and Alere Collapse

Mediation Talks Between Abbott and Alere Collapse

Health care companies will likely continue their battle over a soured merger in Delaware court.

Pharos Capital Acquires TechLab, Leading Developer Of Gastrointestinal Disease Diagnostics

Pharos Capital Acquires TechLab, Leading Developer Of Gastrointestinal Disease Diagnostics

Pharos Capital Group, LLC ("Pharos"), a private equity firm based in Dallas and Nashville, announced it has acquired a controlling position in TechLab, Inc.

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics

The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.

Can Abbott Labs Find a Cure for Its Ailing Shares?

Can Abbott Labs Find a Cure for Its Ailing Shares?

Abbott Labs shares have been all over the place in the last year as the company makes deals. Investors are wondering if they should hold on.

Reaction to St. Jude Cybersecurity Threat May Be Overdone

Reaction to St. Jude Cybersecurity Threat May Be Overdone

The cardiac device maker has filed a lawsuit against the Muddy Waters, claiming the short-seller intentionally disseminated false and misleading information.

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Potential targets of the medical device and diagnostics giant might request stricter parameters when structuring a deal, company followers say.

Alere Asks for September Trial in Case Against Abbott

Alere Asks for September Trial in Case Against Abbott

Alere claims that Abbott is slow-rolling the antitrust process on the companies' merger in an effort to kill the deal.

Alere (ALR) Stock Lower, Says Abbott Has 'Buyer's Remorse' Over Deal

Alere (ALR) Stock Lower, Says Abbott Has 'Buyer's Remorse' Over Deal

In a newly unsealed lawsuit, Alere (ALR) claims that Abbott (ABT) blocked the companies' $7.9 billion merger once it experienced 'buyer's remorse.'